291 related articles for article (PubMed ID: 12524651)
1. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer.
Zhao DS; Valdivia AY; Li Y; Blaufox MD
Semin Nucl Med; 2002 Oct; 32(4):272-5. PubMed ID: 12524651
[TBL] [Abstract][Full Text] [Related]
2. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC
J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716
[TBL] [Abstract][Full Text] [Related]
3. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET).
Kut V; Spies W; Spies S; Gooding W; Argiris A
Am J Clin Oncol; 2007 Feb; 30(1):45-50. PubMed ID: 17278894
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study.
Bradley JD; Dehdashti F; Mintun MA; Govindan R; Trinkaus K; Siegel BA
J Clin Oncol; 2004 Aug; 22(16):3248-54. PubMed ID: 15310768
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules.
Lee ST; Berlangieri SU; Poon AM; Mitchell P; Pathmaraj K; Tabone K; Byrne AJ; O'Keefe GJ; Knight SR; Clarke CP; Scott AM
Intern Med J; 2007 Nov; 37(11):753-9. PubMed ID: 17517082
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer.
Pandit N; Gonen M; Krug L; Larson SM
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):78-84. PubMed ID: 12483413
[TBL] [Abstract][Full Text] [Related]
7. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
8. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
[TBL] [Abstract][Full Text] [Related]
9. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer.
Niho S; Fujii H; Murakami K; Nagase S; Yoh K; Goto K; Ohmatsu H; Kubota K; Sekiguchi R; Nawano S; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Sep; 57(3):328-33. PubMed ID: 17537538
[TBL] [Abstract][Full Text] [Related]
10. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer.
Lee HY; Chung JK; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC
Ann Nucl Med; 2008 May; 22(4):281-6. PubMed ID: 18535878
[TBL] [Abstract][Full Text] [Related]
11. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer.
Shen YY; Shiau YC; Wang JJ; Ho ST; Kao CH
Anticancer Res; 2002; 22(2B):1257-64. PubMed ID: 12168935
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of 18 F-fluorodeoxyglucose - positron emission tomography after treatment in patients with limited stage small cell lung cancer.
Onitilo AA; Engel JM; Demos JM; Mukesh B
Clin Med Res; 2008 Sep; 6(2):72-7. PubMed ID: 18801952
[TBL] [Abstract][Full Text] [Related]
13. An unexpected abdominal 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) in a patient with limited stage small cell lung cancer.
Decoster L; Stroobants S; Verbeken E; Nackaerts K; Vansteenkiste J
J Thorac Oncol; 2008 Feb; 3(2):174-6. PubMed ID: 18303440
[TBL] [Abstract][Full Text] [Related]
14. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
Cheran SK; Herndon JE; Patz EF
Lung Cancer; 2004 Jun; 44(3):317-25. PubMed ID: 15140545
[TBL] [Abstract][Full Text] [Related]
15. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
16. The sensitivity of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of metastatic pulmonary nodules.
Fortes DL; Allen MS; Lowe VJ; Shen KR; Wigle DA; Cassivi SD; Nichols FC; Deschamps C
Eur J Cardiothorac Surg; 2008 Dec; 34(6):1223-7. PubMed ID: 18848459
[TBL] [Abstract][Full Text] [Related]
17. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
Bryant AS; Cerfolio RJ
Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527
[TBL] [Abstract][Full Text] [Related]
18. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
[TBL] [Abstract][Full Text] [Related]
19. Indeterminate pulmonary nodules on CT images in breast cancer patient: the additional value of 18F-FDG PET/CT.
Evangelista L; Panunzio A; Cervino AR; Vinante L; Al-Nahhas A; Rubello D; Muzzio PC; Polverosi R
J Med Imaging Radiat Oncol; 2012 Aug; 56(4):417-24. PubMed ID: 22883649
[TBL] [Abstract][Full Text] [Related]
20. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience.
Blum R; MacManus MP; Rischin D; Michael M; Ball D; Hicks RJ
Am J Clin Oncol; 2004 Apr; 27(2):164-71. PubMed ID: 15057156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
